Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06613191 · ClinicalTrials.gov registry record · Phase 4
Colonoscopy and Antiplatelet Therapy Trial
A Phase 4 study, sponsored by Ochsner Health System.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT06613191 is a Phase 4 study that has not yet begun recruiting, run by Ochsner Health System. The registered enrollment target is 100 participants.
The verdict
NCT06613191, a Phase 4 study, has not yet begun recruiting, sponsored by Ochsner Health System.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.
Interventions
- DRUG Aspirin
- DRUG P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06613191
The ClinicalTrials.gov registry entry for NCT06613191 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ochsner Health System, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT06613191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06613191 about?
NCT06613191 is a clinical study titled "Colonoscopy and Antiplatelet Therapy Trial". Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor \[clopidogrel, prasugrel, or ticagrelor\]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently...
What is the current status of trial NCT06613191?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-10-01. Estimated completion is 2026-06-30.
What interventions are being tested in trial NCT06613191?
The interventions under investigation include: Aspirin (DRUG), P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) (DRUG).
Who is sponsoring clinical trial NCT06613191?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.